{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005802","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.030017+00:00","generated_at":"2026-06-05T07:52:29.506840+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M","bullets":["BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.","Net loss of $14.4M in Q4; net income of $12.7M for full year 2023.","Year-end cash $217.5M; 2024 BRIUMVI net revenue target $220-260M; operating expense ~$250M.","License revenue $141.7M in 2023 driven by $140M Neuraxpharm payment for ex-U.S. rights.","Pipeline: subcutaneous BRIUMVI, azer-cel CAR T in autoimmune disease to start trials in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005802","json":"https://secwatch.observer/filing/0001437749-24-005802.json","markdown":"https://secwatch.observer/filing/0001437749-24-005802.md","text":"https://secwatch.observer/filing/0001437749-24-005802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/0001437749-24-005802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/tgtx20240227_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:52:29.506840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"597bbd80dca9392a764c16b7b30981962359bc69","claim":"TG THERAPEUTICS, INC. updated its the fourth quarter and year ended December 31, 2023 guidance (raised).","evidence_excerpt":"On February 28, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three and twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/0001437749-24-005802-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}